Adoptive Therapy Using Antigen-Specific CD4 T-Cells

Key facts

Sponsor

M.D. Anderson Cancer Center

Principal Investigator

Cassian Yee, MD

M.D. Anderson Cancer Center

Intervention

Ipilimumab(drug)

Eligibility

18 years · All sexes

Timeline

2016

Collaborators

National Institutes of Health (NIH) · National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Liposarcoma

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07377747
  Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
  Australia and New Zealand Sarcoma Association
• RECRUITINGNCT06436846
  Genomic Risk in Retroperitoneal Sarcoma
  Fox Chase Cancer Center
• RECRUITINGPHASE1, PHASE2NCT04785196
  APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
  Ascentage Pharma Group Inc.
• RECRUITINGNCT04699292
  International Prospective Registry on Local Treatment Approaches in MLS
  The Netherlands Cancer Institute
• ACTIVE NOT RECRUITINGPHASE2NCT04557449
  Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
  Pfizer
• ACTIVE NOT RECRUITINGPHASE2NCT04438824
  Palbociclib and INCMGA00012 in People With Advanced Liposarcoma
  Memorial Sloan Kettering Cancer Center
• ACTIVE NOT RECRUITINGPHASE1NCT03361436
  Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery
  OHSU Knight Cancer Institute
• ACTIVE NOT RECRUITINGPHASE2NCT03307616
  Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery
  M.D. Anderson Cancer Center

See all trials for Liposarcoma →